DDInter160 DDInter131
Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Bacillus calmette-guerin substrain tice live antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Bacillus calmette-guerin substrain tice live antigen {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Bacillus calmette-guerin substrain tice live antigen {u} may lead to a major life threatening interaction when taken with {v} Ocrelizumab
Bacillus calmette-guerin substrain tice live antigen may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Etanercept
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab